SearchSearch results for: “日本の検索エンジン 🔍 www.81g.net”

Het milieujaarverslag is voor veel bedrijven bekend terrein. Maar er zijn wijzigingen op komst. In dit blog gaan wij in op die wijzigingen, de achtergrond en de juridische basis van deze verslaglegging en rapportageverplichting.

Tom Barkhuysen schrijft in dit 'Vooraf' van het Nederlands Juristenblad over het belang op zoek te gaan naar de diepere oorzaken van de populariteit van nimby-procedures.

Deze publicatie behandelt een uitspraak van de Rechtbank Noord-Nederland van 12 juni 2025 over de handhaving van de specifieke zorgplichtbepaling uit artikel 11.27 van het Besluit activiteiten leefomgeving (Bal), ruim een jaar na de inwerkingtreding van d

Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.

Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement.

The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU.

Crystal ball gazing into prospective innovation rat races when assessing vertical mergers may soon be all in a day’s work for the European Commission. Innovation was a recurring theme in the Commission’s handling of the Illumina/Grail deal.

Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines.